Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: Estimation of residual transfusion risk and yield of nucleic acid testing

Vox Sanguinis

Volumn 85, Issue 1, 2003, Pages 9-19

  Fang, C T ^a   Field, S P ^b   Busch, M P ^c,d,e   Heyns, Anthon du P ^b  

^a HOLLAND LABORATORY   (United States)

^b SOUTH AFRICAN NATIONAL BLOOD SERVICE   (South Africa)

^c Blood Centers of the Pacific   (United States)

^d Blood Systems Incorporated   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

'detuned' EIA; HCV; HIV; Incidence rate; Nucleic acid testing; Yield

Indexed keywords

ANTIGEN P24; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA;

ADULT; ANTIBODY SCREENING; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; ENDEMIC DISEASE; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; INCIDENCE; MALE; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; SAFETY; SEROCONVERSION; SEROLOGY; SOUTH AFRICA;

ADULT; BLOOD DONORS; BLOOD TRANSFUSION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PREVALENCE; RISK ASSESSMENT; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; SOUTH AFRICA;

EID: 0038351008     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2003.00311.x     Document Type: Article

References (23)

1. Swanevelder R: Blood Resources Survey of Combined Blood Transfusion Services. Internal Report: South African Blood Transfusion Service. Johannesburg, South African Blood Transfusion Service, 1999
2. Heyns A du P: Risk of transmitting HIV and other diseases with a blood transfusion in South Africa. CME (South African Med Assoc) 1999; 17:854-861
3. Swanevelder R: The Impact of the HIV/AIDS Epidemic on Blood Services in South Africa. Internal Report of the South African Blood Transfusion Service to the Department of Health. Johannesburg, South African Blood Transfusion Service, 2001
4. Burin des Roziers N, Coste J, Courouce A-M, Bibollet-Ruche F, Guillard A, Nasr O: Detection of HIV-1 RNA in two consecutive blood donations screened negative for HIV antibodies. Vox Sang 1998; 75:298-302
5. Ling AE, Robbins KE, Brown TM, Dunmire V, Thoe SYS, Wong SY, Leo YS, Teo D, Gallarda J, Phelps B, Chamberland ME, Busch MP, Folks TM, Kalish ML: Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000; 284:210-214
6. Rapicetta M, Dettori S, Kondili LA, Chionne P, Ciccaglione AR, Miceli M, Mannella E: Persistence of HCV RNA in a blood donor with negative antibody assays. Vox Sang 1999; 76:192-193
7. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, Hecht FM, Jack N, Cleghorn FR, Kahn JO, Chesney MA, Busch MP: New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280:42-48
8. Jackson JB, Smith K, Knott C, Korpela A, Simmons A, Piwowar-Manning E, McDonough S, Mimms L, Vargo JM: Sensitivity of the Procleix HIV-1/HCV assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA in a high-risk population. J Clin Microbiol 2002; 40:2387-2391
9. Giachetti C, Linnen JM, Kolk DP, Dockler J, Gillotte-Taylor K, Park M, Ho-Sing-Loy M, McCormick MK, Mimms LT, McDonough SH: Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 2002; 40:2408-2419
10. Vargo J, Smith K, Knott C, Wang S, Fang C, McDonough S, Giachetti C, Caglioti S, Gammon R, Gilbert D, Jackson JB, Richards W, Stramer S, Mimms L: Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. Transfusion 2002; 42:876-885
11. Rawal BD, Degula A, Lebedeva L, Janssen RS, Hecht FM, Sheppard HW, Busch MP: Sensitive/less-sensitive (S/LS) enzyme immunoassay (EIA) for detection of early HIV-1 infection in clinical and epidemiological studies. Equivalence of Organon-Teknika 'Vironostika' EIA (OTV-LS EIA) with Abbott 3A11-LS EIA. J Aids 2003; in press
12. Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, Hannon WH, Mei JV: Performance characteristics of a new less sensitive HIV-1 EIA for use in estimating HIV seroincidence. J Aids 2003; in press
13. Smith R, Heldebrant C: Large scale PCR screening of pooled plasma samples for HIV-1 and HCV; in Brown F, Vyas G (eds): Advances in Transfusion Safety, vol. 102. Basel, Switzerland, Karger 2000:109-111
14. Swanevelder R, Heyns A du P: Impact of the Risk Management Policy on Blood Safety in South Africa [Abstract]. Port Elizabeth, South Africa, The 29th National Blood Transfusion Congress, 2002
15. Busch MP, Kleinman SH: Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: nucleic acid amplification testing and disease transmission. Transfusion 2000; 40:143-146
16. Fiebig EW, Heldebrant C, Smith R, Conrad A, Wright D, Kleinman SH, Busch MP: HIV viremia preceding antibody seroconversion: detection by p24 antigen, minipool nucleic acid amplification tests and individual donation NAT. Transfusion 2000; 40:25S
17. Stramer SL, Porter RA, Brodsky JP, Waldman KJ, Dodd RY, Armstrong T, Griffin GD: Replacement of HIV-1 p24 antigen screening with HIV-1 RNA nucleic acid testing for whole blood donations. Transfusion 1999; 39:2S
18. Stramer SL: Replacement of HIV-1 p24 antigen with HIV NAT. Study on HIV antibody-positive donors. Transfusion 2001; 41:29S
19. Yang Y, Lamendola M-H, Mendoza M, Xu D, Nguyen M, Yeh S, Wu Y, Ku J, Rosenstrans M, Sun R: Performance characteristics of the COBAS AmpliScreen HIV-1 test, version 1.5, an assay designed for screening plasma mini-pools. Transfusion 2001; 41:643-651
20. Law CG, Brookmeyer R: Effects of mid-point imputation on the analysis of doubly censored data. Stat Med 1992; 11:1569-1578
21. Fang CT, Vargo JM, Smith KM, Mimms L, Stramer SL, Caglioti S, Gilbert D, Richards W, Gammon R: Correlation between nucleic acid testing (NAT) and serology in routine blood screening. Transfusion 2001; 41:81S
22. Stramer SL, Davis J, Brodsky J, Wagner A, Parcells M, Beyers M, Kane K, ARC NAT Laboratories: Presentation. Bethesda, MD, FDA NAT Workshop, 2001
23. Kleinman S, Aubuchon JP, Marshall DA, Wong JB, Grima D, Weinsrein MC: Cost-effectiveness of screening donated blood with NAT for HBV, HCV and HIV. Transfusion 2001; 41:1S